Document:

Exhibit
10.34

 

EXHIBIT
G: PLEDGOR ROYALTY AGREEMENT

 

This
Royalty Participation Agreement (the “Pledgor Royalty Agreement”) is made and effective as of the day set forth on
the signature page hereto by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”), PhytoChem
Technologies, Inc. (“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein
as the “Company”), and Brenda Hamilton, an individual (“Pledgor). The Company and the Pledgor are referred to
herein collectively as the “Parties”, or individually as a “Party”.

 

RECITALS

 

WHEREAS,
Company sold a Secured Convertible Promissory Note (the “Note”) to Kahn Family Limited PT I (“Purchaser”)
in a principal aggregate amount of $1,000,000 (the “Principal Amount”) pursuant to that certain Investment Agreement
(“Investment Agreement”), and entered into a Security agreement (the “Security Agreement”) of even date
herewith which is attached as Exhibit C to the Investment Agreement;

 

WHEREAS,
the first four of the Ennea Processors that the Company commercializes and/or monetizes pursuant to the Morgan Agreement shall
serve as collateral (“Collateral Processors”) for the Principal Amount pursuant to the terms of the Security Agreement
and Note attached to the Investment Agreement as Exhibit B;

 

WHEREAS,
in addition to the collateral and consideration provided by the Company, the Purchaser requested additional collateral (the
“Additional Collateral”) in the form of real property as a condition precedent to providing the Principal Amount of
the Note to the Company;

 

WHEREAS,
the Company plans to use the Note proceeds to commercialize and monetize a phytoextractor (the “Ennea Processor”)
that uses certain technologies to separate and/or process the components of hemp to remove and/or modify, purify, dilute and extract
bioactive ingredients and/or remove unwanted substances to produce finished products for a variety of applications pursuant to
an agreement by and between the Company and Owen J. Morgan(“Morgan”) dated February 4, 2019 (the “Morgan Agreement”).

 

WHEREAS,
the Pledgor agreed to provide a mortgage lien covering certain real property (the “Real Property”) as set forth
in the mortgage (the “Mortgage”) and Pledge Agreement (“Pledge Agreement”) of even date herewith as the
Additional Collateral. In exchange for providing the Additional Collateral, the Company desires to pay to the Pledgor the consideration
set forth in the Pledge Agreement which includes a royalty (the “Royalty” or (the “Royalty Payments”)
of eight and one half percent (“8.5%”) of Net Sales (as defined herein) derived from the Collateral Processors so
long as the Principal Amount is outstanding and five percent (5%) thereafter on the first two (2) machines monetized and/or commercialized
pursuant to the Owen Agreement; and

 

WHEREAS,
Pledgor and the Company wish to define the terms and conditions of the Royalty Payments to Pledgor by entering into this Pledgor
Royalty Agreement.

 

THEREFORE,
in consideration of the mutual considerations herein, the receipt of which is mutually acknowledged, the parties hereto agree
as follows:

 

    	 

     

    

 

ARTICLE
1. RECITALS.

 

ARTICLE
1.1 The above recitals are true and correct and made a part hereof.

 

ARTICLE
2. DEFINITIONS.

 

ARTICLE
2.1 ARTICLE 2.1 The Investment Agreement, Note, Purchaser Royalty Agreement, Security Agreement, and the Mortgage are referred
to as the “Ancillary Agreements”. This Pledgor Royalty Agreement and the Ancillary Agreements shall be referred
to collectively as the “Transaction Documents”.

 

ARTICLE
3. PLEDGE.

ARTICLE
3.1 Pledgor has agreed to provide the Additional Collateral for the Note as set forth in the Pledge Agreement.

 

ARTICLE
4. SOURCE, AMOUNT, AND TIMING OF ROYALTY PAYMENTS.

 

ARTICLE
4.1 Commencing upon the fiscal quarter in which revenue is derived directly or indirectly from any of the Collateral Processors,
the Company shall pay to the Pledgor non-refundable Royalty Payments consisting of eight and one half percent (8.5%) of all “Net
Revenue” received by the Company as a result of the commercialization and/or monetization of the Collateral Processors until
such time as the Principal Amount has been paid. At such time as the Principal Amount has been paid to the Purchaser, Pledgor
shall receive non-refundable Royalty Payments consisting of five percent (5%) of “Net Revenue” received by the Company
as a result of the commercialization and/or monetization of the first two Ennea Processors resulting from the Morgan Agreement.

 

For
the purposes of this Pledgor Royalty Agreement, “Net Revenue” shall mean the total Gross Receipts less direct and
indirect expenses. Gross Receipts shall mean revenue from tolling fees and processing fees, product sales, extraction services,
licenses, development, commercialization and/or other commercialization and monetization of the Collateral Processors including
the disposition, sale or rental of the Collateral Processors.

 

ARTICLE
4.2 For the avoidance of doubt, Net Revenue shall be calculated in accordance with GAAP. The Company hereby agrees to use
its commercial best efforts to maximize its Gross Revenue during the term of this Pledgor Royalty Agreement and in the event it
commercializes any other phytoextractors similar to the Collateral Processors , it will not commercialize or monetize such other
equipment until the maximum capacity of the Collateral Processors has been reached. “Gross Revenues” shall also include
all settlement amounts, payment, and damages received by Company which result from litigation or disputes related to or arising
from the sale, license, development, commercialization and/or other monetization of the Collateral Processors.

 

ARTICLE
4.3 The Royalty Payments shall be paid by the Company to the Pledgor within fifteen (15) days after the end of the quarter
in which the Company receives payment for any Net Revenue from the Collateral Processors.

 

ARTICLE
5. INFORMATION REQUIRED TO BE SUPPLIED WITH EACH PAYMENT.

 

ARTICLE
5.1 With each Royalty Payment, the Company shall supply to the Pledgor a detailed and reasonably satisfactory accounting and
reconciliation of how the Royalty Payment was calculated. The Company agrees to have an officer certify each reconciliation and
provide a reconciliation each calendar month during the term of this Pledgor Royalty Agreement regardless of whether any Royalty
Payment is due.

 

    	 

     

    

 

ARTICLE
6. TERM.

 

ARTICLE
6.1 This Pledgor Royalty Agreement shall continue for a period of ten (10) years.

 

ARTICLE
7. NO SALE OR ASSIGNMENT.

 

ARTICLE
9.1 During the term of this Pledgor Royalty Agreement, the Company may not (i) sell (other than ordinary course sales to customers),
assign, or otherwise transfer or encumber the Collateral Processors, (ii) assign or otherwise transfer or encumber this Pledgor
Royalty Agreement, or (iii) create an obligation whereby the Company is required to pay all or a portion of the revenue derived
from the Collateral Processors to any party in priority to the Pledgor without first obtaining the prior written consent of the
Pledgor.

 

ARTICLE
8. EXTRAORDINARY EVENT.

 

ARTICLE
8.1 The Company agrees not to enter into a merger, recapitalization, sale or change of control of the Company or sale transaction
involving all or substantially all of the Company’s equity or assets unless the acquiring or successor entity agrees in
writing to recognize the Pledgor’s rights under this Pledgor Royalty Agreement.

 

ARTICLE
9. NOTICES.

 

ARTICLE
9.1 Any notice required or permitted by this Pledgor Royalty Agreement shall be in writing and shall be deemed sufficient
upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours after being
deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the party to be
notified at such party’s address or facsimile number as set forth on the signature page hereto or as subsequently modified
by written notice.

 

ARTICLE
10. APPLICABLE LAW, VENUE, JURISDICTION.

 

ARTICLE
10.1 GOVERNING LAW AND JURISDICTION. This Pledgor Royalty Agreement shall be governed by and construed in accordance with
the laws of the State of Florida without regard to principles of conflict law applicable to contracts made and to be performed
with such state. Each of the parties hereto accepts for itself to the jurisdiction of Palm Beach County Florida and irrevocably
consents to such jurisdiction in any proceedings, and waives any objection to venue laid therein. Any controversy or claim arising
out of or relating of this Pledgor Royalty Agreement shall be settled by binding arbitration administered by the American Arbitration
Association and judgment on the award entered in any court having jurisdiction. The arbitration proceedings shall be conducted
before a panel of three neutral arbitrators in Palm Beach County, Florida all of whom shall be members of the bar of the state
of Florida, actively engaged in the practice of law for at least ten (10) years. Either Party hereto may apply to the arbitrator
seeking injunctive relief until the arbitration award is rendered or the controversy otherwise resolved. Either Party may, without
waiving any remedy under this Pledgor Royalty Agreement, seek from any court having jurisdiction any interim or provisional relief
that is necessary to protect the rights or property of that party, pending the arbitral tribunal’s determination of the
merits of the controversy. Each party shall bear its own costs, expenses and attorney fees and an equal share of the arbitrators’
and administrative fees of arbitration. Except as may be required by law, neither a party nor an arbitrator may disclose the existence
content or results of any arbitration hereunder without the prior written consent of the Parties. All documents, testimony and
records shall be received, heard and maintained by the arbitrators in secrecy, available for the inspection only of the Parties
to this Royalty Agreement and their respective attorneys and their respective experts who shall agree in advance and in writing
to receive all such information confidentially and to maintain such information in secrecy until such information shall become
generally known. In consideration for and as a material condition of this Pledgor Royalty Agreement, each Party agrees that final
and binding arbitration is the exclusive means for resolving any claim or controversy arising out of or related to this Royalty
Agreement. This Pledgor Royalty Agreement is a waiver of all rights the Parties may have to a civil court action. Accordingly,
only an arbitrator, not a judge or jury, will decide the dispute, although the arbitrator has the authority to award any type
of relief that could otherwise be awarded by a judge or jury.

 

    	 

     

    

 

ARTICLE
10.2 JOINT AND SEVERAL OBLIGATIONS. All obligations of NutraLife and PhytoChem under the Transaction Documents are joint and
not several. All obligations of the Pledgor are several and not joint under the Transaction Documents, and in no event shall the
Pledger have any liability or obligation with respect to the acts or omissions of the Company or any other party to this Agreement.

 

ARTICLE
10.3 FURTHER ASSURANCES. Upon
Pledgor’s reasonable request, the Company and Purchaser shall, at the Company’s sole cost and expense, execute and
deliver all such further documents and instruments, and take all such further acts, necessary to give full effect to this P
Pledgor Royalty Agreement.

 

ARTICLE
10.4 ENTIRE AGREEMENT. This Pledgor
Royalty Agreement constitutes the sole and entire agreement of
the Parties with respect to the subject matter contained herein and therein, and supersedes all prior and contemporaneous understandings,
agreements, representations and warranties, both written and oral, with respect to such subject matter.

 

ARTICLE
10.5 HEADINGS. The headings in this Agreement are for reference only and do not affect
the interpretation of this Pledgor
Royalty Agreement.

 

ARTICLE
10.6 AMENDMENT AND MODIFICATION. No amendment to this Pledgor
Royalty Agreement is effective unless it is in writing and signed
by each Party.

 

ARTICLE
10.7 WAIVER. No waiver under this Pledgor
Royalty Agreement is effective unless it is in writing and signed
by the Party waiving its right. Any waiver authorized on one occasion is effective only in that instance and only for the purpose
stated and does not operate as a waiver on any future occasion. None of the following constitutes a waiver or estoppel of any
right, remedy, power, privilege or condition arising from this Pledgor Royalty Agreement:
(a) any failure or delay in exercising any right, remedy, power or privilege or in enforcing any condition under this Pledgor
Royalty Agreement; or (b) any act, omission or course of dealing
between the Parties.

 

    	 

     

    

 

ARTICLE
10.8 WAIVER OF CONFLICTS.
The Company acknowledges that the Pledgor, Brenda Hamilton and her law firm, Hamilton & Associates Law Group, P.A has in the
past performed, and may continue to perform, legal and/or consulting services for the Company in connection with the Transaction
Documents and the matters and transactions described in the Transaction Documents well as in matters unrelated to the Transaction
Documents. Accordingly, the Company hereby acknowledges that it has been advised by Brenda Hamilton & Hamilton & Associates
Law Group, P.A. to seek the advice of independent legal counsel in connection with the Transaction Documents and transactions
contemplated thereby including the Pledge Agreement, Mortgage and Pledgor Royalty Agreement in which Brenda Hamilton is a party.
Additionally, the Company and each acknowledge that they have had an opportunity to ask for information relevant to this disclosure
and has consulted with independent legal counsel or has had the opportunity to do so and gives its informed consent to Brenda
Hamilton & Hamilton & Associates Law Group, P.A. representation of and/or performance of services for the Company in the
connection with the Transaction Documents and transactions contemplated thereby.

 

ARTICLE
10.9 EQUITABLE REMEDIES. Each Party acknowledges and agrees that (a)
a breach or threatened breach by such Party of any of its obligations would give rise to irreparable
harm to the other Party for which monetary damages would not be an adequate remedy and (b) in
the event of a breach or a threatened breach by such Party of any such obligations, the other Party shall, in addition to any
and all other rights and remedies that may be available to such Party at law, at equity or otherwise in respect of such breach,
be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief
that may be available from a court of competent jurisdiction, without any requirement to post a bond or other security, and without
any requirement to prove actual damages or that monetary damages will not afford an adequate remedy. Each Party agrees that such
Party will not oppose or otherwise challenge the appropriateness of equitable relief or the entry by a court of competent jurisdiction
of an order granting equitable relief, in either case, consistent with the terms of this Section.

 

ARTICLE
10.10 SEVERABILITY.
If any provision of this Pledgor Royalty Agreement is invalid, illegal or unenforceable, the balance of this Pledgor Royalty Agreement
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable
to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
applicable laws governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
permitted rate of interest. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist
upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other
law which would prohibit or forgive the Company from paying all or any portion of the principal of or interest on the Note as
contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance
of the Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such
law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted
to the Pledgor.

 

ARTICLE
10.11 COUNTERPARTS. This Pledgor
Royalty Agreement may be executed in counterparts, each of which
is deemed an original, but all of which together are deemed to be one and the same agreement. A signed copy of this Pledgor
Royalty Agreement delivered by facsimile, e-mail or other means
of electronic transmission is deemed to have the same legal effect as delivery of an original signed copy of this Pledgor
Royalty Agreement.

 

    	 

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Pledgor Royalty Agreement on June 6, 2019.

 

	NUTRALIFE
    BIOSCIENCES, INC.	 	
	 	 	 	 	 
	By:	                              	 	By:	                                               
	 	Edgar
    Ward, Chief Executive Officer 	 	 	Brenda
    Hamilton, an individual
	 	 	 	 	 
	PHYTOCHEM
    TECHNOLOGIES, INC.	 	 	 
	 	 	 	 	 
	By:	 	 	 	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	 
	 	 	 	 
	Address
    for Notice:	 	Address
    for Notice:
	NutraLife
    Biosciences, Inc.	 	1576
    Fan Palm Road Boca Raton Fl 33432 
	Attn:
    Edgar Ward, Chief Executive Officer	 	Phone:
    561-416-8956
	6601
    Lyons Rd. L-6, Coconut Creek, Fl. 33432	 	Email:
    bhamilton@securitieslawyer101.com
	Telephone:
    561-212-3816 	 	 
	Email:
    edgar@NutraFuels.comExhibit
10.35

 

NUTRALIFE
BIOSCIENCES, INC.

INVESTMENT
AGREEMENT 

AMENDED
NOVEMBER 13, 2019

 

This
is an amendment executed on the date set forth on the signature page hereto, to the Investment Agreement dated June 6, 2019, (the
“Original Investment Agreement”) by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”),
PhytoChem Technologies, Inc. (“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred
to herein as the “Company”), and Kahn Family Limited PT II (the “Purchaser”). The Company and the Purchaser
are referred to herein collectively as the “Parties”, or individually as a “Party”.

 

NOW
THEREFORE, the Parties hereby amend and replace the Original Investment Agreement in its entirety and replace it with this
agreement, (the “Investment Agreement”) in exchange for good and valuable consideration the receipt of which is hereby
acknowledged as follows:

 

RECITALS

 

WHEREAS,
the Company obtained certain rights to commercialize and monetize certain technology and phytoextractor equipment known as
the Ennea Processor (“Ennea” or “Ennea Processor”) pursuant to an agreement by and between Owen J. Morgan
(“Morgan”) and the Company dated February 4, 2019 (the “Morgan Agreement”.

 

WHEREAS,
the Ennea Processor uses certain technologies to separate, process and/or extract bioactive compounds including cannabinoids
from hemp and other plants to remove and/or modify, purify, dilute and extract bioactive ingredients and/or remove unwanted
substances to produce finished products for a variety of applications as more fully described on Exhibit A hereto;

 

WHEREAS,
the Company requires capital to manufacture, purchase, monetize and/or commercialize the Ennea;

 

WHEREAS,
the Company issued and sold a full recourse secured convertible promissory note attached hereto as Exhibit B, as amended (the
“Note”) bearing interest at the rate of five point seven five percent (5.75%) per annuum (the “Interest”)
on the principal amount of $1,000,000 (“Principal” or the “Principal Amount”) and the Company intends
to use the Note proceeds to manufacture, purchase, monetize and/or commercialize the Ennea Processors;.

 

WHEREAS,
In addition to the Collateral (as defined in the Note), the first four of the Ennea Processors (“Collateral Processors”)
that the Company monetizes and/or commercializes pursuant to the Morgan Agreement shall serve as collateral for the Principal
Amount pursuant to the terms of the Security Agreement (the “Security Agreement”) attached hereto as Exhibit C;

 

WHEREAS,
at any time while the Note is outstanding, the Purchaser shall have the right to convert the Note into shares of the Company’s
Common Stock at the price of $1.00 per share (the “Conversion Shares”);

 

WHEREAS, as
consideration for the purchase of the Note, the Company: (i) shall pay to the Purchaser the Interest as set forth in the
Note, (ii) issued to the Purchaser, 500,000 shares of its Common Stock, $.0001 par value per share (the “Common
Shares””), and (iii) grant the Purchaser eight and one-half percent (8.5%) of the revenue generated from the
Collateral Processors (the “Royalty” or “Royalties”) while any portion of the Principal Amount is
outstanding and five percent (5%) thereafter as set forth in the Royalty Agreement (the “Purchaser Royalty
Agreement”) attached hereto as Exhibit D;

 

    	 	 	 

     

    

 

WHEREAS,
The Company shall pay the Pledgor certain consideration for the pledge of the Collateral (as defined in the Note) pursuant
to the terms of the Pledge Agreement attached as Exhibit E (the “Pledge Agreement”).

 

WHEREAS,
the Principal Amount is secured by the Collateral and a mortgage on certain real property (the “Mortgage”) attached
hereto as Exhibit F pledged by a third party the (“Pledgor”) and such Mortgage shall be automatically reduced by any
and all consideration of any nature that is paid by the Company to the Purchaser under the Transaction Documents (as defined herein);
and

 

NOW
THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, receipt of
which is hereby acknowledged, the parties to this Investment Agreement agree as follows:

 

ARTICLE
1. RECITALS.

 

ARTICLE
1.1 RECITALS. The above recitals are true and correct and made a part hereof.

 

ARTICLE
2. DEFINITIONS.

 

ARTICLE
2.1 SECURITIES. The Note, the Common Shares and the Conversion Shares (as defined herein) are collectively referred to herein
as the “Securities.”

 

ARTICLE
2.2 CAPITALIZED TERMS. The Note, Security Agreement, Purchaser Royalty Agreement, Pledge Agreement, Mortgage and Pledgor Royalty
Agreement are referred to as the “Ancillary Agreements.” This Investment Agreement and the Ancillary Agreements shall
be referred to collectively as the “Transaction Documents.”

 

Any
capitalized term not defined herein shall have the meaning ascribed to it in Transaction Documents.

 

ARTICLE
3. CONSIDERATION PAID TO THE PURCHASER.

 

ARTICLE
3.1 ADDITIONAL CONSIDERATION. In addition to the Company’s repayment of the Principal Amount and the payment of Interest
to the Company as set forth in the Note, the Company shall pay the following additional consideration to the Purchaser: (i) 500,000
of the Company’s Common Shares upon execution hereof, and (ii) the Royalty pursuant to the terms and conditions set forth
in the Purchaser Royalty Agreement.

 

ARTICLE
3.2 SECURITIES CONSIDERATION. The Common Shares upon issuance to the Purchaser are duly authorized and, when issued and paid
for in accordance with this Investment Agreement and the Transaction Documents, are duly and validly issued, fully paid and nonassessable,
free and clear of all liens. The Company has reserved from its duly authorized capital stock the maximum number of shares of its
common stock issuable upon the conversion of the Note.

 

    	 	 	 

     

    

 

ARTICLE
4. PURCHASE AND SALE OF THE NOTE.

 

ARTICLE
4.1 CLOSING. Subject to the terms and conditions of this Investment Agreement and the Note, the Purchaser agrees to purchase
at the Closing (as defined in 4.2 below) and the Company agrees to sell and issue to the Purchaser, the Note (as amended on the
date hereof) in the Principal Amount.

 

ARTICLE
4.2 PLACE & TIME FOR CLOSING. The purchase and sale of the Original Note occurred on June 6, 2019. This Investment Agreement,
as amended and all exhibits hereto, shall be effective upon execution (the “Closing”).

 

ARTICLE
4.3 CLOSING DELIVERIES. At the Closing, the Company will deliver to the Purchaser signed copies of this Investment Agreement,
and the Ancillary Agreements duly executed according to their terms. The Purchaser previously delivered funds to the Company representing
the Principal Amount and signed copies of the Original Investment Agreement and the Ancillary Agreements duly executed according
to their terms on or about June 6, 2019.

 

ARTICLE
5. SECURITY & COLLATERAL.

 

ARTICL
5.1 THE COLLATERAL PROCESSORS AS SECURITY. The Principal Amount is secured by the Collateral including the Collateral Processors
in accordance with the provisions of the Note and Security Agreement.

 

ARTICLE
5.2 REAL PROPERTY. The Principal Amount shall be further secured by certain real property under the terms of the Pledge Agreement
and Mortgage and such Mortgage shall be reduced by any and all by all consideration of any nature that is paid to the Purchaser
by the Company under the Transaction Documents.

 

ARTICLE
6. REPRESENTATIONS AND WARRANTIES OF THE PARTIES.

 

ARTICLE
6.1 COMPANY REPRESENTATIONS. The Company hereby represents and warrants to the Purchaser that:

 

(i)
ORGANIZATION, GOOD STANDING AND QUALIFICATION. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Florida and has all requisite corporate power and authority to carry on its business as now conducted
and as proposed to be conducted (the “Business”). The Company is duly qualified to transact business
and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business
or properties.

 

(ii)
AUTHORIZATION. All corporate action required on the part of the Company, its officers, directors, and stockholders necessary
for the authorization, execution, and delivery of this Investment Agreement and the Ancillary Agreements and the authorization,
sale, issuance, and delivery of this Investment Agreement and the Ancillary Agreements and the performance of all obligations
of the Company hereunder and under the Ancillary Agreements has been taken or will be taken prior to the Closing. This Investment
Agreement, and each of the Ancillary Agreements, as amended, when executed and delivered, shall constitute valid and legally binding
agreements, enforceable in accordance with their respective terms except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally,
and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

    	 	 	 

     

    

 

(iii)
ISSUANCE OF THE SECURITIES. The Securities upon issuance to the Purchaser will be duly authorized and, when issued and paid
for in accordance with this Investment Agreement and the Ancillary Agreements, will be duly and validly issued, fully paid and
nonassessable, free and clear of all liens. The Company has reserved from its duly authorized capital stock the maximum number
of shares of its common stock issuable upon the conversion of the Note.

 

ARTICLE
6.2 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The Purchaser hereby represents and warrants to the Company that:

 

(i)
AUTHORIZATION. The Purchaser has full power and authority to enter into this Investment Agreement. This Investment Agreement,
when executed and delivered by the Purchaser, will constitute a valid and legally binding obligation of the Purchaser, enforceable
in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating
to the availability of a specific performance, injunctive relief, or other equitable remedies.

 

(ii)
PURCHASE ENTIRELY FOR OWN ACCOUNT. This Investment Agreement is made with the Purchaser in reliance upon the Purchaser’s
representation to the Company, which by the Purchaser’s execution of this Investment Agreement, the Purchaser hereby confirms,
that the Securities to be acquired by the Purchaser are and will be acquired for investment for the Purchaser’s own account,
not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no
present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Investment
Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or
arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any
of the Securities.

 

(iii)
KNOWLEDGE. The Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Securities.

 

(iv)
RESTRICTED SECURITIES. The Purchaser understands that the Securities have not been, and will not be, registered under the
Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent
and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Securities are
“restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws,
the Purchaser must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and
qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser
acknowledges that the Company has no obligation to register or qualify the Securities for resale. The Purchaser further acknowledges
that if an exemption from registration or qualification is available, it may be conditioned on various requirements including,
but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company
which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy.

 

    	 	 	 

     

    

 

arbitration
administered by the American Arbitration Association and judgment on the award entered in any court having jurisdiction. The arbitration
proceedings shall be conducted before a panel of three neutral arbitrators in Palm Beach County, Florida all of whom shall be
members of the bar of the state of Florida, actively engaged in the practice of law for at least ten (10) years. Either Party
hereto may apply to the arbitrator seeking injunctive relief until the arbitration award is rendered or the controversy otherwise
resolved. Either Party may, without waiving any remedy under this Investment Agreement, seek from any court having jurisdiction
any interim or provisional relief that is necessary to protect the rights or property of that party, pending the arbitral tribunal’s
determination of the merits of the controversy. Each party shall bear its own costs, expenses and attorney fees and an equal share
of the arbitrators’ and administrative fees of arbitration. Except as may be required by law, neither a party nor an arbitrator
may disclose the existence content or results of any arbitration hereunder without the prior written consent of the Parties. All
documents, testimony and records shall be received, heard and maintained by the arbitrators in secrecy, available for the inspection
only of the Parties to this Investment Agreement and their respective attorneys and their respective experts who shall agree in
advance and in writing to receive all such information confidentially and to maintain such information in secrecy until such information
shall become generally known. In consideration for and as a material condition of this Investment Agreement, each Party agrees
that final and binding arbitration is the exclusive means for resolving any claim or controversy arising out of or related to
this Investment Agreement. This Investment Agreement is a waiver of all rights the Parties may have to a civil court action. Accordingly,
only an arbitrator, not a judge or jury, will decide the dispute, although the arbitrator has the authority to award any type
of relief that could otherwise be awarded by a judge or jury.

 

ARTICLE
8.4 COUNTERPARTS. This Investment Agreement may be executed in counterparts, each of which is deemed an original, but all
of which together are deemed to be one and the same agreement. A signed copy of the Transaction Documents delivered by facsimile,
e-mail or other means of electronic transmission is deemed to have the same legal effect as delivery of an original signed copy
of this Investment Agreement, if the Party sending such facsimile, e-mail or other means of electronic transmission has received
express confirmation that the recipient Party received the Investment Agreement, not merely an electronic facsimile confirmation
or automatic e-mail reply.

 

ARTICLE
8.5 TITLES AND SUBTITLES. The titles and subtitles used in this Investment Agreement are used for convenience only and are
not to be considered in construing or interpreting this Investment Agreement.

 

ARTICLE
8.6 FORCE MAJEURE. The Company shall not be liable or responsible to Purchaser, nor be deemed to have defaulted under or breached
this Investment Agreement, for any failure or delay in fulfilling or performing any term of this Investment Agreement, if such
failure or delay is caused by or results from acts beyond the Company’s control, including: (i) acts of nature; (ii)
flood, fire, hurricane, earthquake or explosion; (iii) war, invasion, hostilities (whether war is declared or not),
terrorist threats or acts, riot or other civil unrest; (iv) actions, embargos or blockades in effect on or after the date
of this Investment Agreement; (v) national or regional emergency; (vi) strikes, labor stoppages or slowdowns or
other industrial disturbances; (vii) shortages of or delays in receiving raw materials; or (viii) shortage of adequate
power or transportation facilities (each, a “Force Majeure Event”).

 

    	 	 	 

     

    

 

ARTICLE
8.7 NOTICES. Any notice required or permitted by this Investment Agreement shall be in writing and shall be deemed sufficient
upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours after being
deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the Party to be
notified at such Party’s address or facsimile number as set forth on the signature page hereto or as subsequently modified
by written notice.

 

ARTICLE
8.8 AMENDMENTS AND WAIVERS. Any term of this Investment Agreement may only be amended or waived with the written consent of
the Company and the Purchaser.

 

ARTICLE
8.9 SEVERABILITY. If one or more provisions of this Investment Agreement are held to be unenforceable under applicable law,
the parties agree to renegotiate such provision in good faith, in order to maintain the economic position enjoyed by each party
as close as possible to that under the provision rendered unenforceable. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Investment Agreement,
(ii) the balance of the Investment Agreement shall be interpreted as if such provision were so excluded and (iii) the balance
of the Investment Agreement shall be enforceable in accordance with its terms.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Investment Agreement on November 13, 2019.

 

	NUTRALIFE
    BIOSCIENCES, INC.	 	KAHN
    FAMILY LIMITED PT II
	 	 	 	 	 
	By:	 	 	By:
    	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Signature)
	 	 	 	 	 
	 	 	 	 	 
	 	PHYTOCHEM
    TECHNOLOGIES, INC.	 	 	(Print
    Name)
	 	 	 	 	 
	By:	 	 	 	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Print Title)
	  	  	 	 	 
	 	Address
    for Notice:	 	Address
    for Notice:
	 	 	 	 	 
	 	NutraLife
    Biosciences, Inc.	 		 
	 	Attn:
    Edgar Ward, Chief Executive Officer 	 	 	 
	 	6601
    Lyons Rd. L-6 	 		 
	 	Coconut
    Creek, Fl. 33073 	 	Phone: 	 
	 	edgar@NutraFuels.com 	 	 	 
	 	  	 	Email:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]